6.208 Serum Levels of Myonectin Are Lower in Adults with Metabolic Syndrome and Are Negatively Correlated with Android Fat Mass Jorge L. Petro, María Carolina Fragozo-Ramos, Andrés F. Milán, Juan C. Aristizabal, Jaime A. Gallo-Villegas and Juan C. Calderón Special Issue Fatty Acids and Metabolic Syndrome Edited by Dr. Gabriella Calviello and Dr. Simona Serini Article https://doi.org/10.3390/ijms24086874 https://www.mdpi.com/journal/ijms https://www.ncbi.nlm.nih.gov/pubmed/?term=1422-0067 https://www.mdpi.com/journal/ijms/stats https://www.mdpi.com/journal/ijms/special_issues/9SAC8E12IK https://www.mdpi.com https://doi.org/10.3390/ijms24086874 Citation: Petro, J.L.; Fragozo-Ramos, M.C.; Milán, A.F.; Aristizabal, J.C.; Gallo-Villegas, J.A.; Calderón, J.C. Serum Levels of Myonectin Are Lower in Adults with Metabolic Syndrome and Are Negatively Correlated with Android Fat Mass. Int. J. Mol. Sci. 2023, 24, 6874. https://doi.org/10.3390/ ijms24086874 Academic Editors: Gabriella Calviello and Simona Serini Received: 2 February 2023 Revised: 21 February 2023 Accepted: 24 February 2023 Published: 7 April 2023 Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). International Journal of Molecular Sciences Article Serum Levels of Myonectin Are Lower in Adults with Metabolic Syndrome and Are Negatively Correlated with Android Fat Mass Jorge L. Petro 1,2,* , María Carolina Fragozo-Ramos 1 , Andrés F. Milán 1, Juan C. Aristizabal 1 , Jaime A. Gallo-Villegas 3 and Juan C. Calderón 1,* 1 Physiology and Biochemistry Research Group—PHYSIS, Faculty of Medicine, University of Antioquia, Medellín 050010, Colombia 2 Research Group in Physical Activity, Sports and Health Sciences—GICAFS, Universidad de Córdoba, Montería 230002, Colombia 3 Sports Medicine Postgraduate Program, and GRINMADE Research Group, SICOR Center, Faculty of Medicine, University of Antioquia, Medellín 050010, Colombia * Correspondence: jorge.petro@udea.edu.co (J.L.P.); jcalderonv00@yahoo.com (J.C.C.) Abstract: Myonectin has shown beneficial effects on lipid regulation in murine models; therefore, it may have implications in the pathophysiology of metabolic syndrome (MS). We evaluated the relationship between serum myonectin and serum lipids, global and regional fat mass, intramuscular lipid content, and insulin resistance (IR) in adults with metabolic risk factors. This was a cross- sectional study in sedentary adults who were diagnosed with MS or without MS (NMS). Serum myonectin was quantified by enzyme-linked immunosorbent assay, lipid profile by conventional techniques, and free fatty acids (FFA) by gas chromatography. Body composition was assessed by dual-energy X-ray absorptiometry and intramuscular lipid content through proton nuclear magnetic resonance spectroscopy in the right vastus lateralis muscle. IR was estimated with the homeostatic model assessment (HOMA-IR). The MS (n = 61) and NMS (n = 29) groups were comparable in age (median (interquartile range): 51.0 (46.0–56.0) vs. 53.0 (45.5–57.5) years, p > 0.05) and sex (70.5% men vs. 72.4% women). MS subjects had lower serum levels of myonectin than NMS subjects (1.08 (0.87–1.35) vs. 1.09 (0.93–4.05) ng·mL−1, p < 0.05). Multiple linear regression models adjusted for age, sex, fat mass index and lean mass index showed that serum myonectin was negatively correlated with the android/gynoid fat mass ratio (R2 = 0.48, p < 0.01), but not with the lipid profile, FFA, intramuscular lipid content or HOMA-IR. In conclusion, serum myonectin is lower in subjects with MS. Myonectin negatively correlates with a component relevant to the pathophysiology of MS, such as the android/gynoid fat mass ratio, but not with other components such as FFA, intramuscular fat or IR. Keywords: lipids; fatty acids; lipid metabolism disorders; metabolic syndrome; myokine; skeletal muscle 1. Introduction Skeletal muscle secretes myokines with autocrine, paracrine or endocrine action on multiple physiological processes, such as metabolism, inflammation, and muscle devel- opment [1–3]. Serum levels of myokines are affected by conditions such as exercise and diet, and likewise, their levels influence the state of health and disease [2,4]. The study of myokines is key to understanding the role of skeletal muscle in the pathophysiology of conditions such as metabolic syndrome (MS) [5]. Central pathophysiological events of MS include alterations in the compartmental distribution of lipids (e.g., increased visceral adipose tissue (VAT)) and insulin resistance (IR) [6]. The increase in VAT leads to alterations in the profile of free fatty acids (FFAs) Int. J. Mol. Sci. 2023, 24, 6874. https://doi.org/10.3390/ijms24086874 https://www.mdpi.com/journal/ijms https://doi.org/10.3390/ijms24086874 https://doi.org/10.3390/ijms24086874 https://creativecommons.org/ https://creativecommons.org/licenses/by/4.0/ https://creativecommons.org/licenses/by/4.0/ https://www.mdpi.com/journal/ijms https://www.mdpi.com https://orcid.org/0000-0001-5678-1000 https://orcid.org/0000-0002-6657-9989 https://orcid.org/0000-0001-5781-5903 https://orcid.org/0000-0002-6296-5110 https://orcid.org/0000-0002-8695-6972 https://doi.org/10.3390/ijms24086874 https://www.mdpi.com/journal/ijms https://www.mdpi.com/article/10.3390/ijms24086874?type=check_update&version=2 Int. J. Mol. Sci. 2023, 24, 6874 2 of 15 in serum. For instance, elevations in palmitic, palmitoleic, and dihomo-γ-linolenic acids and low concentrations of linoleic and eicosapentaenoic acids correlate with obesity, IR, increased low-density lipoprotein cholesterol (LDL-C), and total cholesterol (TC) [7–9]. In addition, high FFA levels increase ectopic fat in the liver and muscle, which further impairs lipid and glycemic metabolism. Particularly in skeletal muscle, in vivo studies with 1H- nuclear magnetic resonance spectroscopy (1H-MRS) have reported that intramyocellular (IMCL) and extramyocellular lipids (EMCL) are positively correlated with total fat mass and VAT, IR, and mitochondrial dysfunction [10–12]. Several myokines could be protective against metabolic alterations and the risk mark- ers in MS. In this way, irisin, interleukin-6 (IL-6), and apelin improve lipid metabolism and glycemic control [13–15]. Similarly, myonectin (erythroferrone or CTRP15) has been pro- posed as a myokine with an advantageous action on the regulation of lipids, as it reduces circulating levels of total FFA, likely by increasing fatty acid transport in hepatocytes and adipocytes in vitro [16]. In agreement with these findings, myonectin deletion in a murine model increased the accumulation of triacylglycerides (TGs) in white adipose tissue (WAT) while decreasing steatosis in the liver [17]. Additionally, the serum levels of myonectin were reduced in a high-fat diet (HFD)-induced obesity murine model [16]. In human studies, subjects with obesity and type 2 diabetes (T2D) showed lower serum levels than healthy lean subjects, and myonectin levels were inversely associated with indicators of metabolic risk (e.g., high body mass index (BMI), TG, LDL-C, VAT, and IR) [18]. As expected, serum concentrations of myonectin increased in obese women after aerobic exercise training [19]. In contrast, it has also been reported that serum myonectin levels are elevated in obesity, MS, and T2D [20–23], and a positive association was seen between circulating concentrations of myonectin and fat mass, total FFA, TG, and IR while there was a negative association with high-density lipoprotein cholesterol (HDL-C) [23]. These contradictory findings raise questions about the function and metabolic regula- tion of myonectin in humans, which deserves additional study. Furthermore, the potential of myonectin as a lipid regulator in humans may be revealed by extending the analysis to the relationship between myonectin and other indicators that are linked to the pathophysi- ological mechanisms of MS, such as the FFA profile and the intramuscular lipid content. The objective of this study was to evaluate the relationship between serum myonectin and i) lipid components in three different functional and morphological compartments, namely, serum (TG, LDL-C, HDL-C, TC and FFA), body fat depots (global and regional fat mass), and ectopic muscle accumulation (IMCL and EMCL), and ii) IR in adults at metabolic risk. 2. Results 2.1. Characterization of Study Population Ninety individuals were included in this study, of whom 61 were diagnosed with MS (Table 1). The groups were comparable in age, sex, and habits (p > 0.05), while the values of BMI, fasting glucose, insulin, and HOMA-IR were higher in the MS group (p < 0.05). Table 1. Characteristics of the study population. MS (n = 61) NMS (n = 29) p-Value a ES b Demographic Age, years 51.0 (46.0–56.0) 53.0 (45.5–57.5) 0.572 −0.13 Female, n (%) 43 (70.1) 21 (72.4) 0.851 Anthropometry and lean mass Body mass index, kg·m−2 30.6 ± 4.0 27.0 ± 3.5 <0.001 0.94 Waist-to-height ratio 0.61 ± 0.60 0.55 ± 0.06 <0.001 0.89 Waist circumference, cm 94.2 (90.5–102.5) 88.0 (76.1–97.5) <0.001 0.86 TLM, % 56.7 (53.4–61.5) 58.3 (53.0–66.4) 0.543 −0.17 LMI, kg·m−2 17.3 (15.4–18.9) 15.2 (13.7–17.8) 0.003 0.69 ALMI, kg·m−2 7.4 (6.4–8.1) 6.4 (5.6–7.9) 0.009 0.54 Cardiovascular SBP, mmHg 120.5 ± 13.8 119.4 ± 15.7 0.747 0.07 Int. J. Mol. Sci. 2023, 24, 6874 3 of 15 Table 1. Cont. MS (n = 61) NMS (n = 29) p-Value a ES b DBP, mmHg 76.7 ± 10.0 72.4 ± 9.5 0.057 0.44 VO2max, mL·kg−1·min−1 29.2 ± 6.3 31.0 ± 5.8 0.247 0.26 Glycemic control Fasting glucose, mg·dL−1 97.5 (92.7–105.6) 88.6 (84.4–97.3) 0.002 0.72 Fasting insulin, mIU·L−1 14.5 (11.4–19.3) 7.0 (5.1–8.2) <0.001 1.88 HOMA-IR 3.5 (2.9–4.6) 1.7 (1.1–2.0) <0.001 1.71 Habits Physical activity, min·week−1 480.0 (120.0–1020.0) 260.0 (24.0–1960.0) 0.338 −0.21 Smoking, n (%) 4 (6.6) 3 (10.3) 0.677 Alcohol intake, n (%) 10 (16.4) 2 (6.9) 0.324 Medications ACEI or ARA II, n (%) 20 (32.8) 3 (10.3) 0.023 Beta-blockers, n (%) 6 (9.8) 0 (0.0) 0.080 CCB, n (%) 2 (3.3) 0 (0.0) 0.324 Diuretics, n (%) 11 (18.0) 1 (3.4) 0.094 Aspirins, n (%) 3 (4.9) 0 (0.0) 0.224 Cholesterol medications, n (%) 10 (16.4) 0 (0.0) 0.027 Metformin, n (%) 2 (3.3) 0 (0.0) 0.324 TG medications, n (%) 3 (4.9) 0 (0.0) 0.548 Anti-HTN medications, n (%) 22 (36.1) 3 (10.3) 0.011 Data are expressed as mean ± standard deviation, median (interquartile range) or number (%); MS, metabolic syndrome; NMS, no metabolic syndrome; TLM, total lean mass; LMI, lean mass index; ALMI, appendicular lean mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; VO2max, maximal oxygen consumption; HOMA-IR, homeostatic model assessment for insulin resistance; ACEI, angiotensin converting enzyme inhibitor; ARA II, angiotensin II receptor blocker; CCB, calcium channel blockers; TG, triglycerides; HTN, Hypertensive. a p-value: Student’s t-test or Mann–Whitney U test (continuous variables), Chi-square or Fisher test (categorical variables); b ES, effect size calculated with Hedges’ g. 2.2. Results of Serum Lipids, Body Fat Depots and Intramuscular Lipids Content Regarding lipid outcomes, subjects with MS showed higher TG and lower HDL-C levels (p < 0.05). No statistical differences were observed between groups in LDL-C and FFA concentrations (total, saturated, unsaturated, p > 0.05). Fat mass index (FMI), VAT, VAT index (VATI) and Android/Gynoid (And/Gyn) ratio were higher in subjects with MS (p < 0.05). Intramuscular lipid values (IMCL, EMCL, and total), although higher in MS, did not represent a statistically significant difference (p > 0.05) (Table 2). 2.3. Circulating Myonectin in Subjects with and without Metabolic Syndrome Circulating myonectin was lower in subjects with MS than in those without MS (median (interquartile range): 1.08 (0.87–1.35) vs. 1.09 (0.93–4.05) ng·mL−1, p < 0.05, ES = 0.49), as shown in Figure 1. 2.4. Relationship between Myonectin and Lipid Outcomes and Insulin Resistance We then used a sequential statistical approach to evaluate the relationship between myonectin and the study variables. For the sake of comparison with previous contradictory literature and because this is the simplest and most used approach to address the relationship between myonectin and lipid outcomes, we first performed a bivariate correlation analysis that showed no significant correlation between myonectin and any study variable (Table 3). Because some correlation trends (p < 0.1) were observed, a multiple linear regression (MLR)-based approach was then performed for all dependent variables shown in Table 3, in order to conduct a more robust statistical analysis. Independent variables were considered as confounders based on biological plausibility and we rigorously verified the assumption that no collinearity exists between them, and residuals had normal distribution. In a first set of models, adjusted for age and sex, myonectin showed a negative correlation with FMI, VAT, And/Gyn ratio, insulinemia and HOMA-IR (Table 4). Even though myonectin also showed a statistically significant negative correlation with VATI Int. J. Mol. Sci. 2023, 24, 6874 4 of 15 (β = −8.63 g·m−2, p = 0.012), this was the model with the poorest performance (R2 = 0.071, p = 0.095). Table 2. Results of serum lipids, body fat depots, and intramuscular lipids content. MS (n = 61) NMS (n = 29) p-Value a ES b Serum lipids TG, mg·dL−1 182.7 (136.8–219.9) 106.9 (86.0–132.5) <0.001 0.94 LDL-C, mg·dL−1 138.5 (108.5–183.2) 147.0 (119.9–167.7) 0.852 0.13 HDL-C, mg·dL−1 44.7 ± 10.3 50.9 ± 11.6 0.011 −0.58 TC, mg·dL−1 218.8 (189.7–266.6) 216.2 (193.2–235.8) 0.437 0.31 Palmitic acid, µg·dL−1 0.160 (0.134–0.239) 0.152 (0.116–0.175) 0.846 0.14 Stearic acid, µg·dL−1 0.077 (0.062–0.124) 0.077 (0.054–0.115) 0.191 −0.12 Oleic acid, µg·dL−1 0.081 (0.055–0.124) 0.067 (0.052–0.085) 0.543 0.10 Linoleic acid, µg·dL−1 0.105 (0.081–0.169) 0.097 (0.080–0.124) 0.579 −0.25 Araquidonic acid, µg·dL−1 0.050 ± 0.033 0.042 ± 0.021 0.606 0.26 Nervonic acid, µg·dL−1 0.122 (0.063–0.176) 0.065 (0.050–0.138) 0.140 0.67 Total FFA, µg·dL−1 0.477 (0.350–0.763) 0.395 (0.334–0.504) 0.380 −0.15 Fat mass FM, % 40.8 (35.8–44.1) 38.3 (30.4–43.4) 0.400 0.22 FMI, kg·m−2 11.6 (10.5–13.7) 9.6 (8.0–11.7) 0.003 0.65 VAT, cm2 163.0 (124–204) 128 (92.3–145.5) <0.001 0.95 VATI, g·m−2 316.1 (232.6–391.6) 253.6 (181.9–285.0) <0.001 0.97 Android/Gynoid ratio 0.58 (0.48–0.72) 0.50 (0.40–0.64) 0.039 0.50 Intramuscular lipids IMCL, mmol·kg−1 ww 10.2 (5.6–15.5) 8.4 (5.7–13.5) 0.839 0.19 EMCL, mmol·kg−1 ww 30.0 (21.5–41.6) 25.1 (17.1–44.6) 0.571 0.19 TIML, mmol·kg−1 ww 41.5 (27.6–60.0) 36.2 (26.9–60.1) 0.667 0.20 Data are expressed as mean ± standard or median (interquartile range); MS, metabolic syndrome; NMS, no metabolic syndrome; TG, triglycerides; LDL-C, low-density lipoprotein; HDL-C, high-density lipoprotein; TC, total cholesterol; FFA, free fatty acids; FM, fat mass; FMI, fat mass index; VAT, visceral adipose tissue; VATI, visceral adipose tissue index; IMCL, intramyocellular lipid content; EMCL, extramyocellular lipid content; TIML, total intramuscular lipid content (IMCL + EMCL). Note that the median value of TIML is not expected to be equal to the algebraic sum of medians of IMCL + EMCL. a p-value: Student’s t-test or Mann–Whitney; b ES, effect size calculated with Hedges’ g.                                                                           ‐                       ∙ −               ‐   ∙ −               ‐   ∙ −                 −     ∙ −                  μ ∙ −                  μ ∙ −             −      μ ∙ −                  μ ∙ −             −      μ ∙ −                      μ ∙ −                  μ ∙ −             −                                 ∙ −                                 ∙ −                                             ∙ −                   ∙ −                   ∙ −                                                         ‐   ‐     ‐   ‐ ‐                                                                                                                                   ‐     ‐                                                                     ‐                 ∙ −                                                   ‐                             Figure 1. Comparison of serum myonectin concentrations between subjects with MS (metabolic syndrome, blue dots) and without metabolic syndrome (NMS, orange dots). The Hedges’ g between MS and NMS is shown in the above Gardner-Altman estimation plot. Both groups are plotted on the left axes; the mean difference is plotted on a floating axis on the right as a bootstrap sampling distribution (yellow). The mean difference is depicted as a dot; the 95% confidence interval is indicated by the ends of the vertical error bar [24]. The unpaired Hedges’ g between MS and NMS: 0.49 (95.0% CI −0.06–1.0; p = 0.026). Int. J. Mol. Sci. 2023, 24, 6874 5 of 15 Table 3. Correlations between serum myonectin and serum lipids, body composition and intramus- cular lipids content variables. ρ 95% CI a p-Value Serum lipids TG, mg·dL−1 −0.01 −0.22–0.21 0.941 LDL-C, mg·dL−1 −0.20 −0.40–0.02 0.062 HDL-C, mg·dL−1 −0.11 −0.31–0.11 0.305 TC, mg·dL−1 −0.19 −0.39–0.02 0.069 Palmitic acid, µg·dL−1 −0.02 −0.24–0.19 0.826 Stearic acid, µg·dL−1 −0.02 −0.25–0.20 0.832 Oleic acid, µg·dL−1 −0.08 −0.31–0.16 0.524 Linoleic acid, µg·dL−1 −0.09 −0.31–0.13 0.399 Arachidonic, µg·dL−1 −0.22 −0.62–0.27 0.367 Nervonic acid, µg·dL−1 −0.31 −0.59–0.05 0.078 Total fat free acids, µg·dL−1 −0.17 −0.37–0.04 0.105 Body composition Body mass index, kg·m−2 −0.10 −0.31–0.11 0.336 FM, % −0.15 −0.35–0.07 0.167 FMI, kg·m−2 −0.18 −0.37–0.04 0.097 VAT, cm2 −0.08 −0.29–0.14 0.463 VATI, g·m−2 −0.14 −0.34–0.08 0.192 Android/Gynoid ratio 0.02 −0.20–0.23 0.863 TLM, (%) 0.14 −0.08–0.34 0.198 LMI, kg·m−2 0.04 −0.17–0.26 0.676 ALMI, kg·m−2 0.06 −0.16–0.26 0.606 Intramuscular lipids IMCL, mmol·kg−1 ww 0.10 −0.20–0.38 0.497 EMCL, mmol·kg−1 ww −0.09 −0.37–0.21 0.547 TIML, mmol·kg−1 ww <0.01 −0.29–0.29 0.990 Glycemic control Fasting glucose, mg·dL−1 −0.15 −0.35–0.07 0.167 Fasting insulin, mIU·L−1 −0.14 −0.34–0.08 0.188 HOMA-IR −0.15 −0.35–0.06 0.155 a 95% confidence intervals (two-sided); TG, triglycerides; LDL-C, low-density lipoprotein; HDL-C, high-density lipoprotein; TC, total cholesterol; FM, fat mass; FMI, fat mass index; VAT, visceral adipose tissue; VATI, visceral adipose tissue index; TLM, total lean mass; LMI, total lean mass index; ALMI, appendicular lean mass index; IMCL, intramyocellular lipid content; EMCL, extramyocellular lipid content; TIML, total intramuscular lipid content (IMCL + EMCL); HOMA-IR, homeostatic model assessment for insulin resistance. Table 4. Multiple linear regression models showing the relationship between myonectin and fat mass depots and insulin resistance. B a T p-Value 95% CI b R2 Adj. R2 p-Value D-W FMI, kg·m−2 Constant 14.777 6.324 <0.001 10.132 to 19.422 0.344 0.321 <0.001 1.851 Myonectin, ng·mL−1 −0.168 −1.918 0.058 −0.343 to 0.006 Age, years −0.107 −2.489 0.015 −0.193 to −0.022 Female sex 3.077 5.167 <0.001 1.893 to 4.261 VAT, cm2 Constant 201.538 4.241 <0.001 107.060 to 296.016 0.118 0.087 0.013 1.548 Myonectin, ng·mL−1 −3.896 −2.184 0.032 −7.442 to −0.350 Age, years −0.271 −0.310 0.758 −2.014 to 1.471 Female sex −36.557 −3.018 0.003 −60.638 to −12.476 VATI, g·m−2 Constant 338.342 3.761 <0.001 159.483 to 517.200 0.071 0.039 0.095 1.574 Myonectin, ng·mL−1 −8.631 −2.556 0.012 −15.344 to −1.917 Age, years −0.277 −0.167 0.868 −3.576 to 3.023 Female sex −16.341 −0.713 0.478 −61.930 to 29.247 Int. J. Mol. Sci. 2023, 24, 6874 6 of 15 Table 4. Cont. B a T p-Value 95% CI b R2 Adj. R2 p-Value D-W And/Gyn ratio Constant 0.588 4.641 <0.001 0.336 to 0.839 0.419 0.399 <0.001 1.831 Myonectin, ng·mL−1 −0.012 −2.506 0.014 −0.021 to −0.002 Age, years 0.004 1.601 0.113 −0.001 to 0.008 Female sex −0.238 −7.382 <0.001 −0.302 to −0.174 Insulin, mIU·L−1 Constant 27.393 4.671 <0.001 15.735 to 39.052 0.113 0.082 0.016 1.129 Myonectin, ng·mL−1 −0.543 −2.466 0.016 −0.980 to −0.105 Age, years −0.218 −2.013 0.047 −0.433 to −0.003 Female sex −3.077 −2.059 0.043 −6.049 to −0.106 HOMA-IR Constant 6.359 4.012 <0.001 3.208 to 9.51 0.107 0.076 0.020 1.232 Myonectin, ng·mL−1 −0.150 −2.514 0.014 −0.268 to −0.031 Age, years −0.044 −1.514 0.134 −0.102 to 0.014 Female sex −0.902 −2.233 0.028 −1.705 to −0.099 a Non-standardized coefficient (indicates the average change that corresponds to the dependent variable for each unit of change in the independent variable); b 95% confidence interval for β; D-W, Durbin–Watson test; FMI, fat mass index; VAT, visceral adipose tissue; VATI, visceral adipose tissue index; And/Gyn, Android/gynoid fat mass ratio; HOMA-IR, homeostatic model assessment for insulin resistance. The models for the above six variables were then further adjusted for BMI (Model I) or indices of fat and lean mass (Model II, Table 5). In both cases, the correlation of myonectin with FMI, VAT, VATI, insulinemia and HOMA-IR disappeared. Interestingly, only the association with the And/Gyn ratio remained significant, and the models became stronger, since the adjusted R2 increased from 0.399 in Table 4 to 0.446 in Model II (Table 5). The Durbin–Watson value of 2.0 indicates that no autocorrelation existed in model II, highlight- ing its reliability. These findings emphasize a negative relationship between myonectin and central obesity. Table 5. Multiple linear regression model showing the relationship between myonectin and And/Gyn fat mass ratio. B a T p-Value 95% CI b R2 Adj. R2 p-Value D-W And/Gyn Model I Constant 0.259 1.330 0.187 −0.128 to 0.647 0.450 0.424 <0.001 1.954 Myonectin, ng·mL−1 −0.010 −2.059 0.043 −0.019 to 0.000 Age, years −0.233 −7.362 0.000 −0.296 to −0.170 Female sex 0.006 2.270 0.026 0.001 to 0.010 BMI, kg·m−2 0.008 2.181 0.032 0.001 to 0.015 Model II Constant 0.483 2.139 0.035 0.034 to 0.932 0.477 0.446 <0.001 2.051 Myonectin, ng·mL−1 −0.009 −2.008 0.048 −0.019 to 0.00 Age, years 0.005 2.105 0.038 0.00 to 0.010 Female sex −0.325 −5.721 <0.001 −0.437 to −0.212 FMI, kg·m−2 0.019 2.905 0.005 0.006 to 0.033 LMI, kg·m−2 −0.007 −0.807 0.422 0.034 to 0.932 a Non-standardized coefficient (indicates the average change that corresponds to the dependent variable for each unit of change in the independent variable); b 95% confidence interval for β; D-W, Durbin–Watson test; And/Gyn, Android/Gynoid fat mass ratio; BMI, body mass index; FMI, fat mass index; LMI, total lean mass index. 3. Discussion To shed some light on the potential role of myonectin in systemic and local lipid control in humans, we used a comprehensive approach based on two pillars. First, we studied the correlations between this myokine and lipid variables at different functional and morphological compartments of the human body (i.e., circulation, natural fat depots, ectopic/muscle depots). Second, we moved from the simplest to more complex statistical models when addressing all data from the three above mentioned compartments. This approach allowed us to obtain more reliable results and overcome some limitations found Int. J. Mol. Sci. 2023, 24, 6874 7 of 15 in previous works and which may explain the contradictory results already mentioned. We found that (i) subjects with MS had lower serum concentrations than subjects without MS and (ii) after multiple adjustments, myonectin was negatively correlated only with the And/Gyn ratio. 3.1. Subjects with MS Have Lower Serum Concentrations of Myonectin In this regard, the results reported in the literature are mixed. Mice fed a HFD for 12 weeks showed reduced muscle expression and circulating levels of myonectin when compared to mice fed a low-fat diet [16]. Additionally, lower serum levels of myonectin were observed in subjects with T2D than in controls [18]. Similarly, women with poly- cystic ovary syndrome (PCOS), a condition that is associated with a variety of metabolic abnormalities, including obesity, IR, and dyslipidemia, have been reported to have lower serum myonectin concentrations than women without PCOS [25]. All of these results are in agreement with our results. In contrast, Mi et al. [23] reported that subjects with MS have higher values than healthy controls. However, it is noteworthy that subjects from this Asian population had wider age ranges and BMIs (23–82 yr and 15.6–37.59 kg·m−2, respectively) than the participants in our study. The study by Park et al. [26] also claimed an increase in myonectin in obese/diabetic animals. However, instead of evaluating myonectin (CTRP15, UniProtKB: Q4G0M1), they evaluated complement C1q tumor necrosis factor-related protein 5 (CTRP5, UniProtKB: Q9BXJ0), which is not the same protein [27]. Finally, other studies with DT2 [20] and PCOS [28] reported that these patients have higher levels of myonectin than controls (-values as mean ± standard deviation- 82.3 ± 47.6 vs. 45.2 ± 23.5 ng·mL−1, and -values as mean (Q3-Q1)- 96.3 (50.2) vs. 55.6 (20.4) ng·mL−1, respectively). These contradictory results about circulating myonectin in patients with metabolic disorders may arise due to technical and biological factors, such as the different criteria for patient selection and influence of covariates (e.g., age, level of physical activity, IR, body composition, and geographic region). Furthermore, the time of evolution of the metabolic condition may be associated with differential regulation of myonectin. This situation can lead to phenotypes with different characteristics according to the components and complexity of the MS. For instance, subjects with less VAT, more subcutaneous adipose tissue, and still acceptable lean mass (LM) or subjects with more VAT and less LM are associated with differential lipid and glycemic alterations. At least three lines of evidence further support our results, i.e., subjects with MS and IR have lower serum myonectin. On the one hand, myonectin levels increase when metabolic conditions improve. For instance, in obese women, myonectin increased af- ter an 8-week aerobic exercise intervention, which was also associated with a decrease in BMI and IR [19]. In this same vein, Li et al. [29] showed that obese patients had a significant increase in myonectin after a gastric sleeve procedure, together with a de- crease in BMI and improvements in lipid profile and IR. On the other hand, basic research showed that myonectin increases lipid uptake in the adipose tissue and in the liver, sug- gesting a causal link between its reduction and an impairment in lipid metabolism. Finally, conditions such as myosteatosis, inflammation, and IR could be linked to a lower expres- sion/secretion of myonectin, as has been reported with other myokines in cases of metabolic disturbances [30,31]. Considering that our participants were diagnosed de novo by our research team, we propose that in the presence of recent, mild metabolic alterations, my- onectin levels tend to be decreased. It may be that if the disease progresses, a compensatory increase in myonectin tries to cope with ever-increasing circulating lipids and fat depots taken to the limit. An important aspect is that myonectin is a regulator of iron homeostasis [32], which suppresses hepcidin transcription by inhibiting the bone morphogenetic protein/SMAD signaling pathway in hepatocytes [33]. Considering that subjects with MS may have iron overload [34] and high levels of serum ferritin and hepcidin [35], it can be hypothesized that low serum myonectin concentrations may be a feedback mechanism to regulate iron Int. J. Mol. Sci. 2023, 24, 6874 8 of 15 overload in this condition, which may explain our results. This is an avenue that should be addressed in future studies. 3.2. Correlation of Myonectin with Serum Lipids, Fat Mass, Intramuscular Lipids, and Insulin Resistance In the simplest statistical model, i.e., a bivariate correlation analysis, no significant relationship was observed with any lipid variable. These results are similar to those reported by Toloza et al. [22] in a rather similar sample. However, significant correlations between myonectin and various metabolic and lipid outcomes have been reported, but in different directions (i.e., negative and positive) with this type of analysis [18,25,28]. To delve into the relationship between myonectin and lipid variables and IR more powerfully, several MLR analyses were performed. According to our analyses, VAT, And/Gyn, and HOMA-IR were negatively correlated with serum myonectin after multiple adjustments. The best regression model (highest adjusted R2 and lower D-W value) in our study in humans was for And/Gyn. Notably, these findings are in line with those reported in murine models with Erfe gene deletion, which presented an alteration in the distribution of fat deposits, with increases in white adipose tissue (WAT) and the size of adipocytes and decreased steatosis in the liver [17]. To explain these results, based on in vitro assays, we propose that lower levels of myonectin are linked to less activation of RAC-alpha serine/threonine-protein kinase Akt [36] and a lower lipolytic response of the central adipose tissue, leading to increased fat accumulation. In agreement with this, it was recently reported that gene therapy to overexpress Erfe in HFD-induced obese mice decreased the size of adipocytes, improved the lipolytic response to epinephrine in WAT (the most abundant in the central regions), and also in brown adipose tissue (BAT), further increasing the expression of genes related to thermogenesis (e.g., Ucp1, Pgc-1α) [37]. Thus, taking together results in murine models and our results in humans, we can propose that under physiological conditions, myonectin modulates lipid turnover through the transport of FFAs, Akt signaling, and the induction of a lipolytic response in central adipose tissue, therefore contributing to an adequate accumulation and distribution of fat. Then, the reduction of myonectin in subjects with MS may partially explain their increased central obesity. An interesting consequence of these findings is the fact that the relationship between myonectin and IR claimed by previous authors using a simple correlation [18,20,23,25] may not be reliable, since it disappears after adjusting for fat and lean mass. Hence, the relationship between myonectin and IR seems to be mediated by body composition. Alternatively, it may be that the direct effect of myonectin on glucose control is small and can be made visible only under certain conditions. For instance, the overexpression of Erfe in obese mice improved insulin sensitivity and Akt phosphorylation in WAT but not in skeletal muscle [37]. Based on the findings of the previous study, which found no effects on skeletal muscle in mice, it can be proposed that myonectin may have little effect on this tissue in humans, in terms of its lipid metabolism and insulin sensitivity. On the other hand, despite the reported effect of myonectin on plasma fatty acids in murines [16], we did not find a significant correlation with saturated or unsaturated fatty acids in simple correlations or multiple regression models, which is in agreement with previous works [18,23]. The concentrations of myonectin claimed to have such an effect in murines are between two and three orders of magnitude higher than those usually measured in humans, likely indicating that physiological concentrations of myonectin have a low effect on FFA concentrations in humans. A few myokines have shown autocrine effects on muscle lipid metabolism: irisin increases oxidative metabolism in the cell line C2C12 [38], apelin increases enzymatic activity and mitochondrial respiratory capacity in mice [31], and IL-6 stimulates intramus- cular lipolysis of TG and muscle fatty acid oxidation in healthy physically active men [39]. However, in the case of myonectin, we did not find reports in any model (cell lines, animals or humans) evaluating its autocrine effects on intramuscular lipid content. Considering Int. J. Mol. Sci. 2023, 24, 6874 9 of 15 this gap in knowledge, we measured intramuscular lipids through 1H-MRS, which allows a reliable, noninvasive in vivo assessment of IMCL and EMCL lipids, to analyze their rela- tionship with myonectin. Our analyses showed no correlation between myonectin levels and intramuscular lipids. Until we have more information (e.g., the effect of myonectin on fatty acid transporters in muscle), we can conclude that myonectin does not have a measurable effect on intramuscular lipid accumulation. 3.3. Strengths and Limitations We highlight that all measurements were performed with valid and reliable techniques. In the case of ELISA, the proportion of subjects with and without MS was maintained constant in each kit to avoid inter-assay variations that could affect the results. Regarding 1H-MRS analyses, we further performed some quality controls by showing that subjects with MS had higher intramuscular lipid concentrations than younger subjects without risk factors (Supplementary Material Figure S1), similar to what has been previously reported in the literature [12,40], demonstrating the feasibility of the technique to identify subjects with different amounts of intramuscular lipids. Not all participants had intramuscular lipid measurements; however, the sample of subjects evaluated with intramuscular lipids by 1H-MRS remains higher than previous studies with this technique [12,40,41]. Other co- variates, such as iron-related markers, were not evaluated. Future studies should consider this variable. Finally, the relationship of some drugs, such as statins, with myonectin is unknown and may influence the correlation between this myokine and clinical outcomes. Nonetheless, analyses performed excluding the group of participants on cholesterol medi- cations showed the same results as those presented in Table 5 (Supplementary Material Table S1), ruling out any bias due to these medications. To our knowledge, this is the first study to evaluate the relationship between a myokine, specifically myonectin, and lipid variables at different levels of complexity in humans (i.e., serum lipids, total and regional body fat, and intramuscular lipids), which allows a more complete analysis from local to systemic in humans, allowing us to draw stronger conclusions. Additionally, the statistical models were robust, and the comparisons had enough power. Given the scope of this study, the results should be interpreted in the order of the “relationship between variables” and interpretations of causality should be performed with caution. Finally, our results highlight that robust models should be used to draw reliable conclusions on the role of myokines in humans. Performing several simple correla- tions among variables increases the probability of false-positives, and authors may reach misleading conclusions. 4. Materials and Methods 4.1. Study Design This is a cross-sectional study with individuals of both sexes, aged 40 to 60 years, with metabolic risk, as defined by the presence of at least one diagnostic criterion for MS [42]. Elevated waist circumference was determined according to the cutoff values for the Colombian population (≥92 cm in males and ≥84 cm in females) [43]. Subjects were excluded if they consumed supplements (e.g., vitamin D, creatine or whey protein), received insulin, presented with T2D, had a history of cardiovascu- lar/cerebrovascular events, had cancer, had chronic respiratory disease or were pregnant. Vegetarian/vegan participants or those who followed a ketogenic diet and had some physical or mental limitation were excluded. The participants underwent a complete medical history, ergospirometry test, biochem- ical analyses, body composition and intramuscular lipid studies. Subsequently, they were classified into subjects with MS (≥3 MS criteria) or without MS (<3 MS criteria) according to the internationally harmonized criteria of 2009 [42]. Additionally, IR was diagnosed if the homeostatic model assessment (HOMA-IR) value was greater than 2.25 [43]. Int. J. Mol. Sci. 2023, 24, 6874 10 of 15 4.2. Ethics Approval All procedures were approved by the Research Ethics Committee of the Faculty of Medicine at the University of Antioquia (minutes 005 of 15 April 2021) in Medellín (Colombia), in accordance with Resolution number 8430 by the National Ministry of Health of Colombia issued in 1993 and the Ethical Principles for Medical Research Involving Human Subjects outlined in the Declaration of Helsinki in 1975. All participants gave written informed consent. 4.3. Experimental Procedures 4.3.1. Complete Medical History and Physical Examination The clinical history of each participant was recorded, including nutritional aspects and socioeconomic conditions. Physical activity was recorded with the Global Physical Activity Questionnaire (GPAQ) [44]. Cardiorespiratory fitness was assessed through an incremental treadmill ergospirometry test with an open circuit spirometer Oxycon Delta by Jaeger® (VIASYS Health care GmbH, Pullach, Germany), as previously described [45]. Waist circumference was measured with fiberglass anthropometric tape at the midpoint between the lower edge of the rib cage and the iliac crest, according to the World Health Organization recommendations [46], and IR was estimated with the HOMA-IR [5]. 4.3.2. Biochemical Analyses Fasting venous blood samples were collected using serum separator tubes (BD Vacu- tainer 367815, USA) and centrifuged at 1300× g for 15 min at room temperature (Rotofix 32, Hettich, Kirchlengern, Germany). Serum aliquots were kept at −80 ◦C until processing for myonectin and lipids. For myonectin measurements, frozen serum aliquots were thawed with no extra heat, and 40 µL was poured into the wells of a human myonectin enzyme-linked immunosorbent assay (ELISA) plate (MyBioSource, MBS1600042, San Diego, CA, USA). This kit has a detection range of 0.05–10 ng·mL−1 and a sensitivity of 0.03 ng·mL−1 and showed an intra-assay coefficient of variation below 4.0% in our laboratory. All plates were balanced with samples of MS and NMS subjects and were processed by a well-trained investigator blinded to the group coding, according to the supplier’s instructions. Optical density was determined on a plate reader (Varioskan Lux, Thermo Scientific, Waltham, MA, USA) at 450 nm. The lipid profile (TG, LDL-C, HDL-C and TC) was determined by enzymatic anal- ysis using a Dimension® equipment RXL Max (Siemens, Erlangen, Germany). The FFA measurements were performed by lipid extraction following Folch’s method [47]. For this, 40 µL of tridecanoic acid 50 mg·mL−1 and 2 mL of chloroform:methanol (2:1) were added to 100 µL of serum. After saturation with NaCl, sera were centrifuged at 3400 rpm for 7 min, and the organic phase was separated and dried in a bath at 90 ◦C. The dry ex- tract was dissolved in 1 mL of hexane and deposited on aminopropyl columns (200 mg). The separation of the FFA was performed using an Agilent gas chromatograph (7890B, Santa Clara, CA, USA) with a flame ionization detector and a TR-CN100 capillary column (60 m × 250 µm × 0.20 µm) [48]. Helium was used as the carrier gas at a flow rate of 1.4 mL·min−1. For the identification of fatty acids, the retention times of the samples were compared with a standard (FAME Mix of 37 components, Restek, Bellefonte, PA, USA). Here, we report the cis configuration of the most abundant FFA as detected by the system used: palmitic acid (n = 88), stearic acid (n = 79), oleic acid (n = 73), linoleic acid (n = 83), arachidonic acid (n = 19), and nervonic acid (n = 34). 4.3.3. Body Composition Global and regional body composition was assessed using dual-energy X-ray absorp- tiometry (DXA) with the Discovery Wi DXA system® (Hologic, Marlborough, MA, USA) and the Hologic APEX v4.5.3 software (Hologic, USA). All participants were examined in the morning under fasting conditions and a good hydration status (urinary density Int. J. Mol. Sci. 2023, 24, 6874 11 of 15 <1025). We analyzed total fat mass (i.e., fat mass percentage (FM%) and fat mass index (FMI), kg/height(m)2); VAT (cm2) and VAT index (VATI, g·m−2); and the And/Gyn fat mass ratio, as they are well-known predictors of cardiometabolic risk [49,50]. LM indicators were total lean mass (i.e., lean mass percentage (TLM%), lean mass index (LMI), kg·m−2) and appendicular lean mass index (ALMI, kg·m−2). 4.3.4. Quantification of Intramuscular Lipids The intramuscular lipid content was evaluated in the right vastus lateralis muscle (VLM) due to its association with the development of metabolic diseases in humans [51,52], using 1H-MRS and a flexible coil [45], following international recommendations [53]. Spectra were acquired on a Magnetom Skyra magnet with a Flex large 4-channels, 3T receive only, 516 × 224 mm, coil interface and the SyngoMR D13 program (Siemens Healthcare, Erlangen, Germany) as previously reported [5,45,54]. The spectra were pro- cessed with jMRUI [55] v5.2 software (http://www.jmrui.eu, accessed on 1 February 2020). The chemical changes of the protons of the resonances of IMCL and EMCL in the mus- cle were referenced to the signal of the proton of the water (4.7 parts per million, ppm). Then, Gaussian apodization and subtraction of signals other than methylenes (CH2) from IMCL (1.3 ppm) and EMCL (1.5 ppm) were performed on the water-suppressed spectra with the Hankel Lanczos Squares Singular Values Decomposition (HLSVD) method. The quantification of the CH2 signals of IMCL and EMCL was carried out with the Advanced Method for Accurate, Robust, and Efficient Spectral fitting (AMARES). Water amplitude and width were analyzed in spectra obtained without water suppression. The relaxation times (T1 and T2) of IMCL-CH2 and EMCL-CH2 were taken from Valaparla et al. [56]. The abso- lute molar concentration of intramuscular lipids per kilograms of wet weight (mmol·kg−1 ww) was estimated using a validated equation [57,58]: IML = ZW × 106 885.4DT(ZW + P) (1) where IML is the intramuscular lipid content (mmol·kg−1 ww.); Z, methylene-to-water spectral intensity ratio (signals obtained from the spectrum of each patient); W, relative tissue water content to total weight of muscle tissue (0.76); T, weighted density of the TG fatty acids relative to the triolein standard, and converted to molar mass by divid- ing by the triolein standard molecular weight (885.4); D, density of lean muscle tissue (1.05 kg·L−1); and p, relative methylene proton density of tissue fat versus water (0.61) [58]. The reliability of the quantification of the spectra was high for both IMCL (n = 33, r: 0.99 (0.98–0.99), difference in test-retest: 0.40 ± 0.76 mmol·kg−1 ww, p > 0.05; intra- class correlation coefficient, ICC: 0.99 (0.98–0.99)) and EMCL (n = 40, r: 0.98 )0.97–0.99), difference in test-retest: 0.21 ± 3.60 mmol·kg−1 ww, p > 0.05; ICC: 0.98 (0.97–0.99)). In this study, a total of 49 subjects (MS = 36, NMS = 13) had their spectra analyzed for the quantification of intramuscular lipids. Figure 2 summarizes the study design and the evaluation of lipid variables at the three different levels of complexity (serum, body fat depots, and muscle). 4.4. Statistical Analyses The sample size was calculated with G*Power v.3.1.9.7, assuming an effect size of 0.71 (difference of myonectin between the groups, MS vs. NMS) [23], an α of 0.05, a power of 85%, and an allocation ratio of 2. We needed to enroll 27 subjects without MS and 55 with MS. The normality and homoscedasticity of the data were evaluated with the Shapiro– Wilk and Levene tests, respectively. Continuous variables were reported as the mean and standard deviation or median and interquartile range. Categorical variables were expressed as percentages. The comparison between the groups (MS vs. NMS) was performed with Student’s t-test or the Mann–Whitney U test. The comparison of serum myonectin was performed based on the effect size (ES, Hedges’ g) with the novel estimation statistics http://www.jmrui.eu Int. J. Mol. Sci. 2023, 24, 6874 12 of 15 approach, which allows a complementary analysis to increase the precision and quantitative reasoning of the variables in the context of the study [24]. Chi-square or Fisher’s tests were used for the differences between categorical variables. Participants with cardiometabolic risk factors Body composition Intramuscular lipids Myonectin Free fatty acids TG, LDL-C, HDL-C, TC Frequency (ppm) A m p li tu d e ( a .u .) Fat Lean Bone Figure 2. General design of the study, and the evaluation of lipid variables at different levels of complexity. Participants of both sexes, 40–60 years old, were enrolled and evaluated within two weeks. Numbers indicate the experimental procedures: (1) complete medical history, (2) venous blood samples for myonectin, lipid profile and free fatty acids measurements, (3) DXA for global and regional body composition analyses, and (4) 1H-MRS for intramuscular lipid content assessment. 3D structures of the presented molecules: myonectin (Uniprot: Q4G0M1; AlphaFold: AF-Q4G0M1-F1); triolein (PubChem CID: 5497163, modeled with UCSF Chimera, v. 1.16); cholesterol (PubChem CID: 5997); linoleic acid (PubChem CID: 5280450). TG, triglycerides; LDL-C, low-density lipoprotein; HDL-C, high-density lipoprotein; TC, total cholesterol; DXA, dual-energy X-ray absorptiometry. Bivariate correlations were performed with Spearman’s Rho (ρ) test (2-tailed). MLR models were performed adjusting for (i) age and sex, (ii) age, sex, and BMI, and (iii) age, sex, FMI, and LMI. A p < 0.05 was considered as significant in all analyses. Statistical procedures were conducted with SPSS software v.26 (IBM Corp., Armonk, NY, USA) and R v.4.1.0 [59]. 5. Conclusions Myonectin serum levels were lower in participants with MS and negatively correlated with central obesity in subjects with metabolic risk factors. We propose that myonectin is a muscle-secreted factor whose low concentrations may play a role in the pathophysiology of MS, by favoring the accumulation of abdominal fat and the consequent development of IR. Int. J. Mol. Sci. 2023, 24, 6874 13 of 15 Supplementary Materials: The supporting information can be downloaded at: https://www.mdpi. com/article/10.3390/ijms24086874/s1. Author Contributions: J.C.C., J.A.G.-V. and J.L.P. conceived the study design. J.A.G.-V. coordinated the recruitment of participants. A.F.M., J.C.C. and J.L.P. performed the serum myonectin analyzes. J.C.A. supervised the DXA studies. J.L.P. processed the spectra for the quantification of intramuscular lipids. M.C.F.-R., J.L.P. and J.C.C. supervised the FFAs studies. J.L.P., J.C.C. and J.A.G.-V. performed the statistical analysis. J.L.P. and J.C.C. wrote the draft of the manuscript. All authors have read and agreed to the published version of the manuscript. Funding: This study was funded by the CODI-University of Antioquia 58-1-948 (minutes 2020-34909 from 22 February 2021, SIU) and 102 (minutes 2021-40430 from 20 October 2021, IIM), Medellín, Colombia. Funders did not participate in data collection and analysis, manuscript writing or submission. Institutional Review Board Statement: Not applicable. Informed Consent Statement: All procedures were approved by the Research Ethics Committee of the Faculty of Medicine at the University of Antioquia (minutes 005 of 15 April 2021) in Medellin (Colombia), in accordance with Resolution number 8430 by the National Ministry of Health of Colombia issued in 1993 and the Ethical Principles for Medical Research Involving Human Subjects outlined in the Declaration of Helsinki in 1975. All participants gave written informed consent. Data Availability Statement: The data that support the findings of this study are available upon request from the corresponding author. Acknowledgments: The authors express their gratitude to all study participants, the institutions that supported this research, and also to the undergraduate and postgraduate students that supported the collection of samples and spectra. Conflicts of Interest: The authors declare no conflict of interest. References 1. Severinsen, M.C.K.; Pedersen, B.K. Muscle-organ crosstalk: The emerging roles of myokines. Endocr. Rev. 2020, 41, 594–609. [CrossRef] [PubMed] 2. Narvaez-Sanchez, R.; Calderón, J.C.; Vega, G.; Trillos, M.C.; Ospina, S. Skeletal muscle as a protagonist in the pregnancy metabolic syndrome. Med. Hypotheses 2019, 126, 26–37. [CrossRef] [PubMed] 3. Gallo-Villegas, J.A.; Calderón, J.C. Epidemiological, mechanistic, and practical bases for assessment of cardiorespiratory fitness and muscle status in adults in healthcare settings. Eur. J. Appl. Physiol. 2023. [CrossRef] [PubMed] 4. Chen, W.; Wang, L.; You, W.; Shan, T. Myokines mediate the cross talk between skeletal muscle and other organs. J. Cell Physiol. 2021, 236, 2393–2412. [CrossRef] 5. Sánchez, Y.L.; Yepes-Calderón, M.; Valbuena, L.; Milán, A.F.; Trillos-Almanza, M.C.; Granados, S.; Peña, M.; Estrada-Castrillón, M.; Aristizábal, J.C.; Narvez-Sanchez, R.; et al. Musclin is related to insulin resistance and body composition, but not to body mass index or cardiorespiratory capacity in adults. Endocrinol. Metab. 2021, 36, 1055–1068. [CrossRef] 6. Fahed, G.; Aoun, L.; Bou Zerdan, M.; Allam, S.; Bou Zerdan, M.; Bouferraa, Y.; Assi, H.I. Metabolic Syndrome: Updates on pathophysiology and management in 2021. Int. J. Mol. Sci. 2022, 23, 786. [CrossRef] 7. Boden, G. Obesity and free fatty acids. Endocrinol. Metab. Clin. N. Am. 2008, 37, 635–646. [CrossRef] 8. Ni, Y.; Zhao, L.; Yu, H.; Ma, X.; Bao, Y.; Rajani, C.; Loo, L.W.M.; Shvetsov, Y.B.; Yu, H.; Chen, T.; et al. Circulating unsaturated fatty acids delineate the metabolic status of obese individuals. EBioMedicine 2015, 2, 1513–1522. [CrossRef] 9. Bi, X.; Yeo, P.L.Q.; Loo, Y.T.; Henry, C.J. Associations between circulating fatty acid levels and metabolic risk factors. J. Nutr. Intermed. Metab. 2019, 15, 65–69. [CrossRef] 10. Virkamaki, A.; Korsheninnikova, E.; Seppala-Lindroos, A.; Vehkavaara, S.; Goto, T.; Halavaara, J.; Hakkinen, A.-M.; Yki-Jarvinen, H. Intramyocellular lipid is associated with resistance to in vivo insulin actions on glucose uptake, antilipolysis, and early insulin signaling pathways in human skeletal muscle. Diabetes 2001, 50, 2337–2343. [CrossRef] 11. Petersen, K.F.; Dufour, S.; Befroy, D.; Garcia, R.; Shulman, G.I. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N. Engl. J. Med. 2004, 350, 664–671. [CrossRef] [PubMed] 12. Yokota, T.; Kinugawa, S.; Okita, K.; Hirabayashi, K.; Suga, T.; Hattori, M.; Nakagawa, Y.; Oyama-Manabe, N.; Shirato, H.; Tsutsui, H. Lower aerobic capacity was associated with abnormal intramuscular energetics in patients with metabolic syndrome. Hypertens Res. 2011, 34, 1029–1034. [CrossRef] [PubMed] 13. Boström, P.; Wu, J.; Jedrychowski, M.P.; Korde, A.; Ye, L.; Lo, J.C.; Rasbach, K.A.; Boström, E.A.; Choi, J.H.; Long, J.Z.; et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012, 481, 463–468. [CrossRef] [PubMed] https://www.mdpi.com/article/10.3390/ijms24086874/s1 https://www.mdpi.com/article/10.3390/ijms24086874/s1 http://doi.org/10.1210/endrev/bnaa016 http://www.ncbi.nlm.nih.gov/pubmed/32393961 http://doi.org/10.1016/j.mehy.2019.02.049 http://www.ncbi.nlm.nih.gov/pubmed/31010495 http://doi.org/10.1007/s00421-022-05114-y http://www.ncbi.nlm.nih.gov/pubmed/36683091 http://doi.org/10.1002/jcp.30033 http://doi.org/10.3803/EnM.2021.1104 http://doi.org/10.3390/ijms23020786 http://doi.org/10.1016/j.ecl.2008.06.007 http://doi.org/10.1016/j.ebiom.2015.09.004 http://doi.org/10.1016/j.jnim.2019.02.002 http://doi.org/10.2337/diabetes.50.10.2337 http://doi.org/10.1056/NEJMoa031314 http://www.ncbi.nlm.nih.gov/pubmed/14960743 http://doi.org/10.1038/hr.2011.78 http://www.ncbi.nlm.nih.gov/pubmed/21753774 http://doi.org/10.1038/nature10777 http://www.ncbi.nlm.nih.gov/pubmed/22237023 Int. J. Mol. Sci. 2023, 24, 6874 14 of 15 14. Wedell-Neergaard, A.-S.S.; Lang Lehrskov, L.; Christensen, R.H.; Legaard, G.E.; Dorph, E.; Larsen, M.K.; Launbo, N.; Fagerlind, S.R.; Seide, S.K.; Nymand, S.; et al. Exercise-induced changes in visceral adipose tissue mass are regulated by IL-6 signaling: A randomized controlled trial. Cell Metab. 2019, 29, 844–855.e3. [CrossRef] [PubMed] 15. Attane, C.; Foussal, C.; Le Gonidec, S.; Benani, A.; Daviaud, D.; Wanecq, E.; Guzman-Ruiz, R.; Dray, C.; Bezaire, V.; Rancoule, C.; et al. Apelin treatment increases complete fatty acid oxidation, mitochondrial oxidative capacity, and biogenesis in muscle of insulin-resistant mice. Diabetes 2012, 61, 310–320. [CrossRef] [PubMed] 16. Seldin, M.M.; Peterson, J.M.; Byerly, M.S.; Wei, Z.; Wong, G.W. Myonectin (CTRP15), a novel myokine that links skeletal muscle to systemic lipid homeostasis. J. Biol. Chem. 2012, 287, 11968–11980. [CrossRef] 17. Little, H.C.; Rodriguez, S.; Lei, X.; Tan, S.Y.; Stewart, A.N.; Sahagun, A.; Sarver, D.C.; William Wong, G. Myonectin deletion promotes adipose fat storage and reduces liver steatosis. FASEB J. 2019, 33, 8666–8687. [CrossRef] 18. Li, Z.; Yang, Y.L.; Zhu, Y.J.; Li, C.-G.; Tang, Y.Z.; Ni, C.L.; Chen, L.M.; Niu, W.Y. Circulating serum myonectin levels in obesity and type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes 2021, 129, 528–534. [CrossRef] 19. Pourranjbar, M.; Arabnejad, N.; Naderipour, K.; Rafie, F. Effects of aerobic exercises on serum levels of myonectin and insulin resistance in obese and overweight women. J. Med. Life 2018, 11, 381–386. [CrossRef] 20. Li, K.; Liao, X.; Wang, K.; Mi, Q.; Zhang, T.; Jia, Y.; Xu, X.; Luo, X.; Zhang, C.; Liu, H.; et al. Myonectin predicts the development of type 2 diabetes. J. Clin. Endocrinol. Metab. 2018, 103, 139–147. [CrossRef] 21. Shokoohi Nahrkhalaji, A.; Ahmadi, R.; Fadaei, R.; Panahi, G.; Razzaghi, M.; Fallah, S. Higher serum level of CTRP15 in patients with coronary artery disease is associated with disease severity, body mass index and insulin resistance. Arch. Physiol. Biochem. 2019, 128, 276–280. [CrossRef] 22. Toloza, F.J.K.; Mantilla-Rivas, J.O.; Pérez-Matos, M.C.; Ricardo-Silgado, M.L.; Morales-Alvarez, M.C.; Pinzón-Cortés, J.A.; Pérez- Mayorga, M.; Arévalo-Garcia, M.L.; Tolosa-González, G.; Mendivil, C.O.; et al. Plasma levels of myonectin but not myostatin or fibroblast-derived growth factor 21 are associated with insulin resistance in adult humans without diabetes mellitus. Front. Endocrinol. 2018, 9, 5. [CrossRef] 23. Mi, Q.; Li, Y.; Wang, M.; Yang, G.; Zhao, X.; Liu, H.; Zheng, H.; Li, L. Circulating C1q/TNF-related protein isoform 15 is a marker for the presence of metabolic syndrome. Diabetes Metab. Res. Rev. 2019, 35, e3085. [CrossRef] [PubMed] 24. Ho, J.; Tumkaya, T.; Aryal, S.; Choi, H.; Claridge-Chang, A. Moving beyond P values: Data analysis with estimation graphics. Nat. Methods 2019, 16, 565–566. [CrossRef] [PubMed] 25. Demir, İ.; Guler, A. Association of decreased myonectin levels with metabolic and hormonal disturbance in polycystic ovary syndrome. Gynecol. Endocrinol. 2020, 36, 947–950. [CrossRef] [PubMed] 26. Park, S.-Y.; Choi, J.H.; Ryu, H.S.; Pak, Y.K.; Park, K.S.; Lee, H.K.; Lee, W. C1q Tumor Necrosis Factor α-related Protein Isoform 5 is increased in mitochondrial DNA-depleted myocytes and activates amp-activated protein kinase. J. Biol. Chem. 2009, 284, 27780–27789. [CrossRef] 27. Seldin, M.M.; Tan, S.Y.; Wong, G.W. Metabolic function of the CTRP family of hormones. Rev. Endocr. Metab. Disord 2014, 15, 111–123. [CrossRef] 28. Onat, T.; Inandiklioglu, N.; Kara, M.; Serdar Yalvac, E.; Turkler, C.; Ciplak, B.; Altindag, M.M. Increased serum myonectin and irisin levels with myonectin and FNDC5 expressions in polycystic ovary syndrome: A case control study. J. Obs. Gynaecol. 2022, 42, 1381–1387. [CrossRef] 29. Li, L.; Wang, Q.; Qin, C. Serum myonectin is increased after laparoscopic sleeve gastrectomy. Ann. Clin. Biochem. 2020, 57, 360–364. [CrossRef] 30. Ciaraldi, T.P.; Ryan, A.J.; Mudaliar, S.R.; Henry, R.R. Altered myokine secretion is an intrinsic property of skeletal muscle in type 2 diabetes. PLoS ONE 2016, 11, e0158209. [CrossRef] 31. Vinel, C.; Lukjanenko, L.; Batut, A.; Deleruyelle, S.; Pradère, J.-P.; Le Gonidec, S.; Dortignac, A.; Geoffre, N.; Pereira, O.; Karaz, S.; et al. The exerkine apelin reverses age-associated sarcopenia. Nat. Med. 2018, 24, 1360–1371. [CrossRef] [PubMed] 32. Kautz, L.; Jung, G.; Valore, E.V.; Rivella, S.; Nemeth, E.; Ganz, T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat. Genet. 2014, 46, 678–684. [CrossRef] [PubMed] 33. Arezes, J.; Foy, N.; McHugh, K.; Sawant, A.; Quinkert, D.; Terraube, V.; Brinth, A.; Tam, M.; LaVallie, E.R.; Taylor, S.; et al. Erythroferrone inhibits the induction of hepcidin by BMP6. Blood 2018, 132, 1473–1477. [CrossRef] [PubMed] 34. Bozzini, C.; Girelli, D.; Olivieri, O.; Martinelli, N.; Bassi, A.; De Matteis, G.; Tenuti, I.; Lotto, V.; Friso, S.; Pizzolo, F.; et al. Prevalence of body Iron excess in the metabolic syndrome. Diabetes Care 2005, 28, 2061–2063. [CrossRef] 35. Martinelli, N.; Traglia, M.; Campostrini, N.; Biino, G.; Corbella, M.; Sala, C.; Busti, F.; Masciullo, C.; Manna, D.; Previtali, S.; et al. Increased serum hepcidin levels in subjects with the metabolic syndrome: A population study. PLoS ONE 2012, 7, e48250. [CrossRef] 36. Otaka, N.; Shibata, R.; Ohashi, K.; Uemura, Y.; Kambara, T.; Enomoto, T.; Ogawa, H.; Ito, M.; Kawanishi, H.; Maruyama, S.; et al. Myonectin is an exercise-induced myokine that protects the heart from ischemia-reperfusion injury. Circ. Res. 2018, 123, 1326–1338. [CrossRef] 37. Qi, Z.; Xia, J.; Xue, X.; Liu, W.; Huang, Z.; Zhang, X.; Zou, Y.; Liu, J.; Liu, J.; Li, X.; et al. Codon-optimized FAM132b gene therapy prevents dietary obesity by blockading adrenergic response and insulin action. Int. J. Obes. 2022, 46, 1970–1982. [CrossRef] 38. Vaughan, R.A.; Gannon, N.P.; Barberena, M.A.; Garcia-Smith, R.; Bisoffi, M.; Mermier, C.M.; Conn, C.A.; Trujillo, K.A. Characteri- zation of the metabolic effects of irisin on skeletal muscle in vitro. Diabetes Obes. Metab. 2014, 16, 711–718. [CrossRef] http://doi.org/10.1016/j.cmet.2018.12.007 http://www.ncbi.nlm.nih.gov/pubmed/30595477 http://doi.org/10.2337/db11-0100 http://www.ncbi.nlm.nih.gov/pubmed/22210322 http://doi.org/10.1074/jbc.M111.336834 http://doi.org/10.1096/fj.201900520R http://doi.org/10.1055/a-0896-8548 http://doi.org/10.25122/jml-2018-0033 http://doi.org/10.1210/jc.2017-01604 http://doi.org/10.1080/13813455.2019.1675713 http://doi.org/10.3389/fendo.2018.00005 http://doi.org/10.1002/dmrr.3085 http://www.ncbi.nlm.nih.gov/pubmed/30303269 http://doi.org/10.1038/s41592-019-0470-3 http://www.ncbi.nlm.nih.gov/pubmed/31217592 http://doi.org/10.1080/09513590.2020.1751109 http://www.ncbi.nlm.nih.gov/pubmed/32314610 http://doi.org/10.1074/jbc.M109.005611 http://doi.org/10.1007/s11154-013-9255-7 http://doi.org/10.1080/01443615.2021.1980516 http://doi.org/10.1177/0004563220942263 http://doi.org/10.1371/journal.pone.0158209 http://doi.org/10.1038/s41591-018-0131-6 http://www.ncbi.nlm.nih.gov/pubmed/30061698 http://doi.org/10.1038/ng.2996 http://www.ncbi.nlm.nih.gov/pubmed/24880340 http://doi.org/10.1182/blood-2018-06-857995 http://www.ncbi.nlm.nih.gov/pubmed/30097509 http://doi.org/10.2337/diacare.28.8.2061 http://doi.org/10.1371/journal.pone.0048250 http://doi.org/10.1161/CIRCRESAHA.118.313777 http://doi.org/10.1038/s41366-022-01189-x http://doi.org/10.1111/dom.12268 Int. J. Mol. Sci. 2023, 24, 6874 15 of 15 39. Wolsk, E.; Mygind, H.; Grøndahl, T.S.; Pedersen, B.K.; van Hall, G. IL-6 selectively stimulates fat metabolism in human skeletal muscle. Am. J. Physiol.-Endocrinol. Metab. 2010, 299, E832–E840. [CrossRef] 40. Valaparla, S.; Boone, G.; Ripley, E.; Giuseppe, D.; Duong, T.; Abdul-Ghani, M.; Clarke, G. Skeletal muscle lipid quantification in lean and diabetic subjects using in vivo proton MR spectroscopy. Int. J. Cancer Ther. Oncol. 2014, 2, 020239. [CrossRef] 41. Savage, D.B.; Watson, L.; Carr, K.; Adams, C.; Brage, S.; Chatterjee, K.K.; Hodson, L.; Boesch, C.; Kemp, G.J.; Sleigh, A. Accumulation of saturated intramyocellular lipid is associated with insulin resistance. J. Lipid Res. 2019, 60, 1323–1332. [CrossRef] 42. Alberti, K.G.; Eckel, R.H.; Grundy, S.M.; Zimmet, P.Z.; Cleeman, J.I.; Donato, K.A.; Al., E.; Fruchart, J.-C.C.; James, W.P.T.; Loria, C.M.; et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International. Circulation 2009, 120, 1640–1645. [CrossRef] [PubMed] 43. Gallo Villegas, J.A.; Ochoa Múnera, J.E.; Balparda Arias, J.K.; Aristizábal Ocampo, D. Puntos de corte del perímetro de la cintura para identificar sujetos con resistencia a la insulina en una población colombiana. Acta Médica Colomb. 2013, 38, 118–126. [CrossRef] 44. Bull, F.C.; Maslin, T.S.; Armstrong, T. Global Physical Activity Questionnaire (GPAQ): Nine country reliability and validity study. J. Phys. Act. Health 2009, 6, 790–804. [CrossRef] [PubMed] 45. Gallo-Villegas, J.; Castro-Valencia, L.A.; Pérez, L.; Restrepo, D.; Guerrero, O.; Cardona, S.; Sánchez, Y.L.; Yepes-Calderón, M.; Valbuena, L.H.; Peña, M.; et al. Efficacy of high-intensity interval- or continuous aerobic-training on insulin resistance and muscle function in adults with metabolic syndrome: A clinical trial. Eur. J. Appl. Physiol. 2022, 122, 331–344. [CrossRef] [PubMed] 46. World Health Organization. Obesity: Preventing and managing the global epidemic: Report of a WHO consultation. In World Health Organization Technical Report Series; World Health Organization: Geneva, Switzerland, 2000; Volume 894, pp. 1–253. 47. Folch, J.; Lees, M.; Sloane Stanley, G.; Slone Stanley, G.H. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 1957, 226, 497–509. [CrossRef] 48. Agren, J.J.; Julkunen, A.; Penttilä, I. Rapid separation of serum lipids for fatty acid analysis by a single aminopropyl column. J. Lipid Res. 1992, 33, 1871–1876. [CrossRef] 49. Okosun, I.S.; Seale, J.P.; Lyn, R. Commingling effect of gynoid and android fat patterns on cardiometabolic dysregulation in normal weight American adults. Nutr. Diabetes 2015, 5, e155. [CrossRef] 50. Amato, M.C.; Giordano, C. Visceral adiposity index: An indicator of adipose tissue dysfunction. Int. J. Endocrinol. 2014, 2014, 1–7. [CrossRef] 51. Londoño, F.J.; Calderón, J.C.; Gallo, J. Association between thigh muscle development and the metabolic syndrome in adults. Ann. Nutr. Metab. 2012, 61, 41–46. [CrossRef] 52. Olsen, D.B.; Sacchetti, M.; Dela, F.; Ploug, T.; Saltin, B. Glucose clearance is higher in arm than leg muscle in type 2 diabetes. J. Physiol. 2005, 565, 555–562. [CrossRef] [PubMed] 53. Krššák, M.; Lindeboom, L.; Schrauwen-Hinderling, V.; Szczepaniak, L.S.; Derave, W.; Lundbom, J.; Befroy, D.; Schick, F.; Machann, J.; Kreis, R.; et al. Proton magnetic resonance spectroscopy in skeletal muscle: Experts’ consensus recommendations. NMR Biomed. 2021, 34, e4266. [CrossRef] [PubMed] 54. Vega, G.; Ricaurte, G.; Estrada-Castrillón, M.; Reyngoudt, H.; Cardona, O.M.; Gallo-Villegas, J.A.; Narvaez-Sanchez, R.; Calderón, J.C. In vivo absolute quantification of carnosine in the vastus lateralis muscle with 1H MRS using a surface coil and water as internal reference. Skelet. Radiol. 2023, 52, 157–165. [CrossRef] [PubMed] 55. Stefan, D.; Cesare, F.D.; Andrasescu, A.; Popa, E.; Lazariev, A.; Vescovo, E.; Strbak, O.; Williams, S.; Starcuk, Z.; Cabanas, M.; et al. Quantitation of magnetic resonance spectroscopy signals: The jMRUI software package. Meas. Sci. Technol. 2009, 20, 104035. [CrossRef] 56. Valaparla, S.K.; Gao, F.; Daniele, G.; Abdul-Ghani, M.; Clarke, G.D. Fiber orientation measurements by diffusion tensor imaging improve hydrogen-1 magnetic resonance spectroscopy of intramyocellular lipids in human leg muscles. J. Med. Imaging 2015, 2, 026002. [CrossRef] 57. Szczepaniak, L.S.; Babcock, E.E.; Schick, F.; Dobbins, R.L.; Garg, A.; Burns, D.K.; McGarry, J.D.; Stein, D.T. Measurement of intracellular triglyceride stores by H spectroscopy: Validation in vivo. Am. J. Physiol. 1999, 276, E977–E989. [CrossRef] 58. Weis, J.; Johansson, L.; Ortiz-Nieto, F.; Ahlström, H. Assessment of lipids in skeletal muscle by LCModel and AMARES. Magn. Reson Imaging 2009, 30, 1124–1129. [CrossRef] 59. R Core Team R: A Language and Environment for Statistical Computing. Available online: https://www.r-project.org (accessed on 24 November 2022). Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. http://doi.org/10.1152/ajpendo.00328.2010 http://doi.org/10.14319/ijcto.0202.39 http://doi.org/10.1194/jlr.M091942 http://doi.org/10.1161/CIRCULATIONAHA.109.192644 http://www.ncbi.nlm.nih.gov/pubmed/19805654 http://doi.org/10.36104/amc.2013.73 http://doi.org/10.1123/jpah.6.6.790 http://www.ncbi.nlm.nih.gov/pubmed/20101923 http://doi.org/10.1007/s00421-021-04835-w http://www.ncbi.nlm.nih.gov/pubmed/34687360 http://doi.org/10.1016/S0021-9258(18)64849-5 http://doi.org/10.1016/S0022-2275(20)41345-8 http://doi.org/10.1038/nutd.2015.5 http://doi.org/10.1155/2014/730827 http://doi.org/10.1159/000339267 http://doi.org/10.1113/jphysiol.2004.081356 http://www.ncbi.nlm.nih.gov/pubmed/15774531 http://doi.org/10.1002/nbm.4266 http://www.ncbi.nlm.nih.gov/pubmed/32022964 http://doi.org/10.1007/s00256-022-04149-8 http://www.ncbi.nlm.nih.gov/pubmed/35978163 http://doi.org/10.1088/0957-0233/20/10/104035 http://doi.org/10.1117/1.JMI.2.2.026002 http://doi.org/10.1152/ajpendo.1999.276.5.E977 http://doi.org/10.1002/jmri.21900 https://www.r-project.org Introduction Results Characterization of Study Population Results of Serum Lipids, Body Fat Depots and Intramuscular Lipids Content Circulating Myonectin in Subjects with and without Metabolic Syndrome Relationship between Myonectin and Lipid Outcomes and Insulin Resistance Discussion Subjects with MS Have Lower Serum Concentrations of Myonectin Correlation of Myonectin with Serum Lipids, Fat Mass, Intramuscular Lipids, andInsulin Resistance Strengths and Limitations Materials and Methods Study Design Ethics Approval Experimental Procedures Complete Medical History and Physical Examination Biochemical Analyses Body Composition Quantification of Intramuscular Lipids Statistical Analyses Conclusions References